Stock Analysis, Dividends, Split History

ITRI / Itron, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price62.45
Volume199,800.00
Market Cap ($M)2,354.07
Enterprise Value ($M)2,990.77
Book Value ($M)662.76
Book Value / Share16.86
Price / Book3.43
NCAV ($M)-1,063.84
NCAV / Share-27.07
Price / NCAV-2.31
Share Statistics
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 38,771,000
Common Shares Outstanding 38,784,060
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.04
Return on Equity (ROE)0.10
Balance Sheet (mrq) ($M)
Assets2,643.57
Liabilities1,960.59
Quick Ratio1.18
Current Ratio1.51
Income Statement (mra) ($M)
Sales Revenue Goods Net1,813,925,000.00
Sales Revenue Services Net204,272,000.00
Sales Revenue Net2,018,197,000.00
Operating Income151.43
Net Income60.25
Earnings Per Share Basic1.48
Earnings Per Share Diluted1.45
Cash Flow Statement (mra) ($M)
Cash From Operations191.35
Cash from Investing-148.18
Cash from Financing191.35
Identifiers and Descriptors
CUSIP465741106
Central Index Key (CIK)780571
Related CUSIPS
465741956 465741906

Split History

Stock splits are used by Itron, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

9h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

9h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

10h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Itron's (ITRI) Q2 Earnings Beat Estimates, Revenues Up Y/Y

2018-08-07 zacks
Itron, Inc. (ITRI - Free Report) delivered second-quarter 2018 non-GAAP earnings of 51 cents beating the Zacks Consensus Estimate by 2 cents. The figure soared a whopping 292.3% on a sequential basis but declined 28.2% year over year. Revenues came in $585.9 million, which grew 16.4% from the year-ago quarter but decreased 3.5% sequentially. The figure also missed the Zacks Consensus Estimate of $591. (12-0)

Itron, Inc. (ITRI) CEO Philip Mezey on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha
Good day, everyone. And welcome to the Itron Incorporated Q2 2018 Earnings Conference Call. Please note that today's conference is being recorded. For opening remarks, I would like to turn the call over to Ms. Barbara Doyle. Please go ahead. (4-0)

Itron (ITRI) Tops Q2 Earnings Estimates

2018-08-06 zacks
Itron (ITRI - Free Report) just came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.71 per share a year ago. These figures are adjusted for non-recurring items. (1-0)

Landis+Gyr: Global Leader In Smart Meters

2018-06-19 seekingalpha
Swiss-based Landis+Gyr (OTCPK:LDGYY) is the largest manufacturer of smart grid monitors in the world. The company was taken public last July as Toshiba needed to liquidate. About half of the United States' energy users do not have smart monitors which leaves room for growth over the next few years.

Itron (ITRI) Down 12.7% Since Earnings Report: Can It Rebound?

2018-06-13 zacks
It has been about a month since the last earnings report for Itron, Inc. (ITRI - Free Report) . Shares have lost about 12.7% in that time frame. (35-1)

Silicon Investor Message Boards

This table lists all message boards related to ITRI / Itron, Inc. on message board site Silicon Investor.

Citrix Systems (CTXS) Citrix Systems (CTXS) Citrix Systems (CTXS) ITRI: Itron, Inc. ITRI: Itron, Inc. ITRI: Itron, Inc.
VTTX (Vitrix, Inc -- Internet Based ASP) VTTX (Vitrix, Inc -- Internet Based ASP) VTTX (Vitrix, Inc -- Internet Based ASP) Vitria Technology (VITR) Vitria Technology (VITR) Vitria Technology (VITR)
VITR: Vitria Technology, Inc. VITR: Vitria Technology, Inc. VITR: Vitria Technology, Inc. Itron (ITRI) - wireless utility meter reading Itron (ITRI) - wireless utility meter reading Itron (ITRI) - wireless utility meter reading
GraphOn(UFAC)...The Next Citrix?? GraphOn(UFAC)...The Next Citrix?? GraphOn(UFAC)...The Next Citrix??
CUSIP: 465741106